本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Arcutis Biotherapeutics Inc.

17.29
-0.4000-2.26%
盘后17.450.1550+0.90%19:31 EDT
成交量:140.70万
成交额:2,429.96万
市值:20.73亿
市盈率:-23.28
高:17.71
开:17.63
低:16.92
收:17.69
52周最高:18.15
52周最低:8.03
股本:1.20亿
流通股本:8,558.07万
量比:0.64
换手率:1.64%
股息:- -
股息率:- -
每股收益(TTM):-0.7427
每股收益(LYR):-1.1578
净资产收益率:-57.33%
总资产收益率:-13.46%
市净率:14.92
市盈率(LYR):-14.93

数据加载中...

2024/03/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/04

重要事件披露

Form 8-K - Current report
2024/02/29

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/28

重要事件披露

Form 8-K - Current report
2024/02/27

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/02/27

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/02/27

重要事件披露

Form 8-K - Current report
2024/02/15

重要事件披露

Form 8-K - Current report
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/13

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/13

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/12

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/06

SEC问询函

Form CORRESP - Correspondence
2024/01/31

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/01/25

SEC问询函

Form CORRESP - Correspondence
2024/01/11

重要事件披露

Form 8-K - Current report